Oshima, Yuji http://orcid.org/0000-0001-6284-977X
Ishibashi, Yumi
Umeda, Naoyasu
Nagata, Tatsuo
Yoshida, Shigeo
Uchio, Eiichi
Kondo, Hiroyuki
Sonoda, Koh-hei
Ishibashi, Tatsuro
Funding for this research was provided by:
Japan Society for the Promotion of Science (#Kiban C 17K11454)
NOVARTIS Foundation (Japan) for the Promotion of Science
Article History
Received: 13 October 2020
Accepted: 12 January 2021
First Online: 23 January 2021
Ethics approval and consent to participate
: The protocol was approved by the Institutional Review Board/Ethics Committee of each participating hospital (Kyushu University, Kurume University, Fukuoka University, University of Occupational and Environmental Health) and the NPO Clinical Research Network Fukuoka Ethics Committee (13-E09). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Written informed consent was obtained from all the participants included in the study.
: Not applicable.
: The author(s) have made the following disclosure(s): Y.O: Grants – Novartis Pharma, during the conduct of the study; Grants and Personal fees- Novartis Pharma, Bayer, Santen Pharmaceutical Co., Ltd. outside the submitted work.Y.I: Personal fees- Bayer, Santen Pharmaceutical Co., Ltd. outside the submitted work.N.U: Novartis Pharma, during the conduct of the study; Grants and Personal fees- Novartis Pharma outside the submitted work.T.N: Grants and personal fees- Santen Pharmaceutical Co., Ltd., Alcon, Novartis Pharma, Bayer, Otsuka Pharmaceutical, outside the submitted work.S.Y: Grants - Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. outside the submitted work.E.U: Novartis Pharma, during the conduct of the study.H.K: Grants and Personal fees- Santen Pharmaceutical Co., Ltd., Alcon, AMO Japan, Novartis, Pharma Bayer, Kowa Pharmaceutical, Senju Pharmaceutical, Otsuka Pharmaceutical, RE Medical, outside the submitted work.K.S: Grants – HOYA Corporation, Santen Pharmaceutical Co., Ltd. outside the submitted work.T.I: Novartis Pharma, during the conduct of the study; Grants - Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. outside the submitted work.